Skip to content

Public FDA record

Z-0008-2008: CVI OZ Palm Injector, used to perfuse contrast media into vessels for angiographic procedures. Ref : OZ

Recall record Z-0008-2008 for Lemaitre Vascular, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0008-2008
Company in FDA record
Lemaitre Vascular, Inc.
FDA classification date
Oct 4, 2007
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Sterility of device may be compromised due to breach in sterile barrier.

Source facts

Action
The firm issued a "Adivsory Notice" to accounts 7/18/07, advising them to examine inventory and remove product with defective packaging. The firm issued an updated notification dated 9/24/07 advising users to return recalled lots instead of conducting an examination of the product at the user site.
Initiated
2007-07-18
Root cause
Package design/selection
Terminated
2008-09-08
Distribution
Worldwide, including USA, Canada, Netherlands, and Germany.
Recall number
Z-0008-2008
Recall status
Terminated
CDRH record ID
54520
FDA classified
2007-10-04
Recall event number
38894

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗